Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Swanton

Showing results (61-70 of 439) with videos related to

Pageof 44
Sort By:
The Journal of Experimental Medicine|September 16, 2018
Kidney cancer: The next decadeSamra Turajlic, Charles Swanton, Chris Boshoff
Nature Reviews. Clinical Oncology|January 4, 2018
Determinants and clinical implications of chromosomal instability in cancerLaurent Sansregret, Bart Vanhaesebroeck, Charles Swanton
Current Cancer Drug Targets|August 20, 2010
Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapiesSarah Barton, Naureen Starling, Charles Swanton
The New England Journal of Medicine|September 20, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Marco Gerlinger, Larry Norton, Charles Swanton
Molecular Oncology|April 18, 2026
Molecular cancer prevention: Intercepting diseaseCharlotte Grieco, Tej Pandya, Charles Swanton
BMJ (Clinical Research Ed.)|July 31, 2025
No time to waste-we need to start cancer clinical trials fasterEllie Jones, Catherine Elliott, Charles Swanton
Cancer Letters|November 13, 2012
Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challengesStuart Horswell, Nicholas Matthews, Charles Swanton
Nature Reviews. Clinical Oncology|July 4, 2018
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detectionChristopher Abbosh, Nicolai J Birkbak, Charles Swanton
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Targeting polo-like kinase: learning too little too late?David Olmos, Charles Swanton, Johann de Bono
Nature Reviews. Clinical Oncology|September 21, 2022
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challengesImran Noorani, Paul S Mischel, Charles Swanton
Pageof 44

Showing results (61-70 of 439) with videos related to

Sort By:
Pageof 44
The Journal of Experimental Medicine|September 16, 2018
Kidney cancer: The next decadeSamra Turajlic, Charles Swanton, Chris Boshoff
Nature Reviews. Clinical Oncology|January 4, 2018
Determinants and clinical implications of chromosomal instability in cancerLaurent Sansregret, Bart Vanhaesebroeck, Charles Swanton
Current Cancer Drug Targets|August 20, 2010
Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapiesSarah Barton, Naureen Starling, Charles Swanton
The New England Journal of Medicine|September 20, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Marco Gerlinger, Larry Norton, Charles Swanton
Molecular Oncology|April 18, 2026
Molecular cancer prevention: Intercepting diseaseCharlotte Grieco, Tej Pandya, Charles Swanton
BMJ (Clinical Research Ed.)|July 31, 2025
No time to waste-we need to start cancer clinical trials fasterEllie Jones, Catherine Elliott, Charles Swanton
Cancer Letters|November 13, 2012
Cancer heterogeneity and "the struggle for existence": diagnostic and analytical challengesStuart Horswell, Nicholas Matthews, Charles Swanton
Nature Reviews. Clinical Oncology|July 4, 2018
Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detectionChristopher Abbosh, Nicolai J Birkbak, Charles Swanton
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Targeting polo-like kinase: learning too little too late?David Olmos, Charles Swanton, Johann de Bono
Nature Reviews. Clinical Oncology|September 21, 2022
Leveraging extrachromosomal DNA to fine-tune trials of targeted therapy for glioblastoma: opportunities and challengesImran Noorani, Paul S Mischel, Charles Swanton
Pageof 44